Who Paid My Doc
Robert Hannum
General Practice Tampa, FL Doctor of Osteopathy
NPI 1700943008 CMS profile 168526
3450 Palencia Dr Apt 1004, Tampa, FL 33618
General payments
$2,252
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$1,760,832
Through program year 2019, Robert Hannum of Tampa, FL is reported in the CMS Open Payments database as having received $2,252 across 12 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,760,832 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 89th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2019 | General | $2,252 | 12 |
Beside peers
- Robert Hannum
- General Practice median
- Middle half of General Practice
- National median
In program year 2025, general payments to Robert Hannum were reported at $0. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.
Show as a table
| Year | Robert Hannum | General Practice median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,252 | $107 | $37–$285 | $163 |
| 2020 | $0 | $75 | $25–$213 | $114 |
| 2021 | $0 | $93 | $30–$272 | $132 |
| 2022 | $0 | $103 | $36–$279 | $149 |
| 2023 | $0 | $106 | $34–$276 | $160 |
| 2024 | $0 | $114 | $39–$290 | $164 |
| 2025 | $0 | $106 | $35–$292 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 7 drugsPart D claims
161
Drug cost
$4,019
Branded share of claims
68.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine | Brand | 83 | $2,344 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 14 | $785 | |
| Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine | Brand | 14 | $477 | |
| Lorazepam | Generic | 14 | $251 | |
| Alprazolam | Generic | 12 | $81 | |
| Sumatriptan Succinate | Generic | 11 | $55 | |
| Fluoxetine Hcl | Generic | 13 | $26 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.
Records
12 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
General Practice in Florida
Practitioners in the same specialty and state, ranked by reported value.
All General Practice
Everyone recorded under this specialty, nationwide.
Doctors in Florida
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.